STRATAGENE AFFINITYSCRIPT REVERSE TRANSCRIPTASE, 2000 U/μl ULTRA-PURE DNAse RNAse FREE WATER (10 x 500 ML BOTTLES) LIVE/DEAD™ Fixable Aqua Dead Cell Stain Kit GAG Potential T cell Epitopes (PTE) peptides pool Before receiving the conditioning regimen, she was given a dose of rituximab for prophylaxis against post-transplant lymphoproliferative disease associated with Epstein-Barr virus (EBV).Ĭhemicals, peptides, and recombinant proteins Graft-versus-host disease (GVHD) prophylaxis consisted of mycophenolate mofetil for 28 days and tacrolimus until day 180 ( Figure 1B). The transplant conditioning regimen included fludarabine, melphalan, total body irradiation (4 Gray), and antithymocyte globulin (ATG). The cord blood graft contained 2 × 10 7 nucleated cells per kg and 2.2 × 10 5 CD34 cells per kg of the recipient’s weight. In 2017, she underwent a haplo-cord transplant consisting of CD34-selected cells from the peripheral blood of the haploidentical adult donor, followed by the 5/8 HLA-matched CCR5Δ32/Δ32 CBU. We also identified a related haploidentical adult donor with CCR5 wild-type allele to support a haplo-cord transplant with early transient engraftment. We searched the StemCyte registry and identified five CCR5Δ32/Δ32-mutated compatible CBUs with a 4/8 or higher HLA match. CCR5Δ32/Δ32 haplo-cord transplant achieved remission and a possible HIV-1 cure for a person of diverse ancestry, living with HIV-1, who required a stem cell transplant for acute leukemia. Immune reconstitution was associated with (1) loss of detectable replication-competent HIV-1 reservoirs, (2) loss of HIV-1-specific immune responses, (3) in vitro resistance to X4 and R5 laboratory variants, including pre-transplant autologous latent reservoir isolates, and (4) 18 months of HIV-1 control with aviremia, off antiretroviral therapy, starting at 37 months post-transplant. Peripheral blood chimerism was 100% CCR5Δ32/Δ32 cord blood by week 14 post-transplant and persisted through 4.8 years of follow-up. We report the first remission and possible HIV-1 cure in a mixed-race woman who received a CCR5Δ32/Δ32 haplo-cord transplant (cord blood cells combined with haploidentical stem cells from an adult) to treat acute myeloid leukemia (AML). Previously, two men were cured of HIV-1 through CCR5Δ32 homozygous (CCR5Δ32/Δ32) allogeneic adult stem cell transplant.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |